Pazopanib: a novel treatment option for aggressive fibromatosis

Bulut G., Ozluk A., ERDOĞAN A. P., Uslu R., Elmas N., Karaca B.

CLINICAL SARCOMA RESEARCH, vol.6, pp.1-4, 2016 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 6
  • Publication Date: 2016
  • Doi Number: 10.1186/s13569-016-0061-3
  • Journal Name: CLINICAL SARCOMA RESEARCH
  • Journal Indexes: Emerging Sources Citation Index (ESCI)
  • Page Numbers: pp.1-4
  • Manisa Celal Bayar University Affiliated: No

Abstract

Background: Aggressive fibromatosis (AF), also known as desmoid tumor, is an uncommon soft tissue neoplasm. AF does not metastasize, but it is locally invasive and its propensity for recurrence after conservative resection is well documented. No effective cytotoxic treatment has been reported, hence there is a need for novel treatment strategies. Case presentation: We present the case of an AF successfully treated with an oral tyrosine kinase inhibitor, pazopanib, with mild side effects. As far as we know, this is the first case of AF with complete response to pazopanib. Conclusion: Pazopanib might be an effective treatment option for AF.